Skip to main content

Table 1 Baseline clinical characteristics of the study patients

From: Enhanced expression of ROCK in left atrial myocytes of mitral regurgitation: a potential mechanism of myolysis

  MR sinus (n = 10) MR AF (n = 12) p value
Age (years) 56 ± 10 67 ± 7 0.007
Male (%) 2 (20.0 %) 10 (83.3 %) 0.008
Creatinine (mg/dl) 0.7 ± 0.2 1.2 ± 0.4 <0.001
White blood cell count (103/uL) 6.5 ± 1.9 5.2 ± 1.3 0.069
Body mass index (kg/m2) 24.4 ± 2.1 23.9 ± 3.1 0.628
Hypertension (%) 3 (30.0 %) 6 (50.0 %) 0.415
Diabetes mellitus (%) 2 (20.0 %) 3 (25.0 %) 1.000
Dyslipidemia (%) 5 (50.0 %) 1 (8.3 %) 0.043
Heart failure NYHA classification 2.9 ± 0.3 2.9 ± 0.5 0.961
Functional class II (%) 1 (10.0 %) 2 (16.7 %)  
Functional class III (%) 9 (90.0 %) 9 (75.0 %)  
Functional class IV (%) 0 (0.0 %) 1 (8.3 %)  
Advanced heart failure (%) 9 (90.0 %) 10 (83.3 %) 0.571
Aortic valve disease (%) 0 (0.0 %) 2 (16.7 %) 0.481
Tricuspid valve disease (%) 2 (20 %) 7 (58.3 %) 0.099
Left atrial pressure (mmHg) 17.0 ± 8.4 19.3 ± 7.9 0.424
Left atrial diameter (mm) 41.9 ± 5.7 51.7 ± 8.6 0.007
Left atrial ejection fraction (%) 51.6 ± 17.7 38.2 ± 13.6 0.041
Left ventricular end-diastolic diameter (mm) 54.6 ± 5.3 62.4 ± 8.6 0.029
Left ventricular end-systolic diameter (mm) 34.3 ± 5.9 42.5 ± 7.7 0.019
Left ventricular ejection fraction (%) 66.1 ± 7.9 58.5 ± 10.4 0.086
Beta-blockers (%) 1 (10.0 %) 4 (33.3 %) 0.323
Calcium channel blockers (%) 1 (10.0 %) 4 (33.3 %) 0.323
Angiotensin converting enzyme inhibitors or angiotensin II receptor blockers (%) 10 (100.0 %) 10 (83.3 %) 0.481
Statins (%) 1 (10.0 %) 0 (0.0 %) 0.455
  1. Data are presented as mean ± SD or number (percentage).
  2. NYHA, New York Heart Association.